Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EQL Pharma AB ( (SE:EQL) ) just unveiled an announcement.
EQL Pharma AB has announced that it will publish its interim report for the third quarter of its 2025/26 financial year on Tuesday, 3 February 2026, and will follow this with a video conference presentation on 4 February at 10:00 CET. The online event, led by CEO and President Axel Schörling and including a question-and-answer session, is aimed at current and potential shareholders and is intended to provide greater transparency on the company’s financial performance and operational progress, underscoring its efforts to engage capital markets and maintain investor confidence as it advances its pipeline of niche generics in the Nordic and European markets.
More about EQL Pharma AB
EQL Pharma AB is a Lund-based pharmaceutical company specializing in the development and sale of niche generic prescription drugs, including hospital products, that are medically equivalent to original medicines. The company has 46 niche generics launched across the Nordic markets, a substantial pipeline of additional products planned for 2026 and beyond, and operates mainly in the Nordic and wider European markets through collaborations with leading contract manufacturers and major pharmaceutical companies in the EU and Asia. EQL Pharma is listed on the Nasdaq Stockholm stock market.
Average Trading Volume: 31,747
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.57B
Find detailed analytics on EQL stock on TipRanks’ Stock Analysis page.